Evaluation of IGF1 serum levels in malignant melanoma and healthy subjects

Anticancer Research

Volumn 34, Issue 9, 2014, Pages 5217-5220

  Kucera, Radek ^a   Treskova, Inka ^b   Vrzalova, Jindra ^a   Svobodova, Sarka ^a   Topolcan, Ondrej ^a   Fuchsova, Radka ^a   Rousarova, Milena ^a   Treska, Vladislav ^a   Kydlicek, Tomas ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Breslow score; IGF1; Melanoma; Sentinel node metastasis

Indexed keywords

SOMATOMEDIN C; BIOLOGICAL MARKER;

ADOLESCENT; ADULT; ARTICLE; BRESLOW SCORE; CANCER PROGNOSIS; CHILD; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; HUMAN; IMMUNORADIOMETRIC ASSAY; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MELANOMA; MIDDLE AGED; ONCOLOGICAL PARAMETERS; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RADIOIMMUNOASSAY KIT; SCORING SYSTEM; SENTINEL LYMPH NODE METASTASIS; UPREGULATION; AGED; BLOOD; CASE CONTROL STUDY; IGF1; LYMPH NODE METASTASIS; METABOLISM; PATHOLOGY; PROGNOSIS; SENTINEL LYMPH NODE BIOPSY; SENTINEL NODE METASTASIS; VERY ELDERLY; YOUNG ADULT;

BRESLOW SCORE; IGF1; MELANOMA; SENTINEL NODE METASTASIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHILD; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LYMPHATIC METASTASIS; MELANOMA; MIDDLE AGED; PROGNOSIS; SENTINEL LYMPH NODE BIOPSY; YOUNG ADULT;

EID: 84908680713     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Bennett DC: How to make a melanoma: what do we know of the primary clonal events? Pigment Cell Melanoma Res 21(1): 27-38, 2008.
2. Ferlay J, Parkin DM and Steliarova-Foucher E: Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46(4): 765-781, 2010.
3. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D and Bray F: Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur J Cancer 49(6): 1374-1403, 2013.
4. Larson Z: Insulin-like growth factor 1 (IGF-1): a growth hormone. Mol Pathol 54: 311-316, 2001.
5. Pollak M: Insulin and insulin-like growth factor signaling in neoplasia. Nat Rev Cancer 8(12): 915-928, 2008.
6. Brabant G and Wallaschofski H: Normal levels of serum IGF-I: determinants and validity of current reference ranges. Pituitary 10( 2): 129-133, 2007.
7. Kucera R, Cerna M, Narsanska A, Svobodova S, Strakova M, Vrzalova J, Fuchsova R, Treskova I, Kydlicek T, Treska V, Pecen L, Topolcan O and Pazdiora P: Growth factors and breast tumors, comparison of selected growth factors with traditional tumor markers. Anticancer Res 31(12): 4653-4656, 2011.
8. Alberti C, Chevenne D, Mercat I, Josserand E, Armoogum- Boizeau P, Tichet J and Leger J: Serum concentrations of insulin-like growth factor (IGF-1) and IGF binding protein-3 (IGFBP-3), IGF-1/IGFBP-3 ratio, and markers of bone turnover: reference values for French children and adolescents and z-score comparability with other references. Clin Chem 57(10): 1424-1435, 2011.
9. Rosario PW: Normal values of serum IGF-1 in adults: results from a Brazilian population. Arq Bras Endocrinol Metabol 54( 5): 477-481, 2010.
10. Morimoto LM, Newcomb PA, White E, Bigler J and Potter JD: Variation in plasma insulin-like growth factor-1 and insulin-like growth factor binding protein-3: genetic factors. Cancer Epidemiol Biomarkers Prev 14(6): 1394-1401, 2005.
11. Park SL, Setiawan VW, Kanetsky PA, Zhang ZF, Wilkens LR, Kolonel LN and Le Marchand L: Serum insulin-like growth factor-I and insulin-like growth factor binding protein-3 levels with risk of malignant melanoma. Cancer Causes Control 22(9): 1267-1275, 2011.
12. Santonocito C, Paradisi A, Capizzi R, Concolino P, Lavieri MM, Lanza Silveri S, De Luca D, Catricala C, Di Carlo A, Zuppi C, Ameglio F and Capoluongo E: Insulin-like growth factor I (CA) repeats are associated with higher melanoma's Breslow index but not associated with the presence of the melanoma. A pilot study. Clin Chim Acta 390(1-2): 104-109, 2008.
13. Frenkel S, Zloto O, Peer J and Barak V: Insulin-like growth factor-1 as a predictive biomarker for metastatic uveal melanoma in humans. Invest Ophtalmol Vis Sci 54(1): 490-493, 2013.
14. Breslow A: Prognostic factors in the treatment of cutaneous melanoma. J Cutan Pathol 6(3): 208-12, 1979.
15. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A Jr., Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA and Thompson JF: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19(16): 3635-3648, 2001.
16. Peterson JE, Kulik G, Jelinek T, Reuter CW, Shannon JA and Weber MJ: Src phosphorylates the insulin-like growth factor type I receptor on the autophosphorylation sites. Requirement for transformation by src. J Biol Chem 271(49): 31562-31571, 1996.
17. Malaguarnera R and Belfiore A: The emerging role of insulin and insulin-like growth factor signaling in cancer stem cells. Front Endocrinol 5(10): doi: 10.3389/fendo.2014.00010, 2014.
18. Abbasi NR, Shaw HM, Rigel DS, Friedman RJ, McCarthy WH, Osman I, Kopf AW and Polsky D: Early diagnosis of cutaneous melanoma: revisiting the ABCD criteria. JAMA 292(22): 2771-2776, 2004.